Efficacy of the combination of endostar with chemotherapy on stage IVb and recurrent metastatic cervical cancer.
10.11817/j.issn.1672-7347.2020.190321
- Author:
Feng GUO
1
;
Caizhi CHEN
2
;
Ye LIANG
2
;
Shuyun MA
2
;
Wen ZOU
3
Author Information
1. Department of Oncology, Second Xiangya Hospital, Central South University, Changsha 410011, China. 168212295@csu.edu.cn.
2. Department of Oncology, Second Xiangya Hospital, Central South University, Changsha 410011, China.
3. Department of Oncology, Second Xiangya Hospital, Central South University, Changsha 410011, China. zouwen29w@csu.edu.cn.
- Publication Type:Randomized Controlled Trial
- Keywords:
cervical cancer;
endostar;
metastasis;
recombinant human endostatin;
recurrence
- MeSH:
Antineoplastic Combined Chemotherapy Protocols/adverse effects*;
Cisplatin/therapeutic use*;
Endostatins;
Female;
Humans;
Lung Neoplasms/pathology*;
Neoplasm Recurrence, Local/pathology*;
Neoplasm Staging;
Recombinant Proteins;
Uterine Cervical Neoplasms
- From:
Journal of Central South University(Medical Sciences)
2020;45(12):1412-1418
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:To observe the efficacy and adverse reactions of the combination of endostar with chemotherapy in the treatment of advanced (IVb) and recurrent metastatic cervical cancer.
METHODS:Forty-four patients with recurrent and metastatic cervical cancer, who were admitted to the Second Xiangya Hospital, Central South University from December 2016 to December 2018 were randomly divided into an experimental group and a control group (22 cases in each group). The control group was given gemcitabine plus cisplatin (GP) or docetaxel plus cisplatin (DP) treatment, the experimental group was treated with endostar on the basis of the control group.
RESULTS:The objective response rate (ORR) was 42.9% in the experimental group and 22.7% in the control group. There was no significant difference between the 2 groups (
CONCLUSIONS:Compared with chemotherapy alone, endostar combined with chemotherapy can prolong the median progression-free survival, with higher ORR and similar adverse reactions.
